Page 13 - Adjuvant News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article The addition of olaparib (Lynparza) to standard treatment significantly improved disease-free survival (DFS) in patients with early, high-risk HER2-negative breast cancer and germline BRCA mutations, according to results from a phase III study. Interim findings from the OlympiA trial showed that patients receiving the PARP inhibitor had a 42% reduction in the risk of invasive DFS versus patients receiving placebo (HR 0.58, 95% CI 0.41-0.82), and a 43% reduction in the risk of distant DFS (HR 0.57, 95% CI 0.39-0.83), reported Andrew Tutt, MB, ChB, PhD, of the Institute of ...

email article Single-agent immune checkpoint inhibition after surgery reduced the risk of disease recurrence or death in patients with high-risk clear cell renal cell carcinoma (RCC), findings from a phase III study showed. The KEYNOTE-564 trial met its primary endpoint, demonstrating that adjuvant pembrolizumab (Keytruda) following nephrectomy significantly increased disease-free survival (DFS) versus placebo (HR 0.68, 95% CI 0.53-0.87, P=0.001), reported Toni Choueiri, MD, of the Dana-Farber Cancer Institute in Boston. At 1 and 2 years, respectively, DFS rates were 85.7% and 77.3% wi...

Eurocine Vaccines' Adjuvant Technology Endocine is evaluated with a vaccine candidate against COVID-19 Eurocine Vaccines has signed a Material Transfer Agreement regarding the evaluation of Endocine together with a vaccine candidate against COVID-19 STOCKHOLM, May 19, 2021 /PRNewswire/ -- Eurocine Vaccines has signed an evaluation agreement, a Material Transfer Agreement, with an innovative, North American, small public company, regarding the evaluation of Endocine together with a vaccine candidate against COVID-19. Studies in one or two animal species will be conducted to study both potency ...

Photo Credit: IANS IANSLive London, April 23 (IANS) A novel malaria vaccine developed by the University of Oxford has demonstrated high-level efficacy of 77 per cent in its Phase 2 trials. To get full access of the story, click here to subscribe to IANS News Service © 2021 IANS India Private Limited. All Rights Reserved. The reproduction of the story/photograph in any form will be liable for legal action. For news, views and gossips, follow IANS at Twitter. Update: 23-April-2021

Coronavirus | Hyderabad CSIR lab helped develop key molecule for Covaxin Updated: Updated: February 28, 2021 23:58 IST Bharat Biotech had approached the Indian Institute of Chemical Technology to develop the synthetic route for the adjuvant molecule TLR 7/8 with indigenous chemicals at an affordable price and with highest purity. Share Article IICT chief S. Chandrasekhar with Bharat Biotech CMD Krishna Ella. Photo: Special Arrangement   Bharat Biotech had approached the Indian Institute of Chemical Technology to develop the synthetic route for the adjuvant molecule TLR 7/8 with indigenous ...